Penumbra, Inc. (PEN) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-02-25

Business type: Treadmill

How it makes money

Penumbra earns revenue by selling specialized medical devices to healthcare providers, driven by ongoing portfolio innovation and direct sales expansion.

Penumbra generates revenue by developing, manufacturing, and marketing novel products for challenging medical conditions such as ischemic stroke and pulmonary embolism. It sells these products primarily through its direct sales organization in the United States, most of Europe, Canada, Australia, and Singapore, as well as through select international distributors. Revenue reached $1,403.7 million in 2025, up from $1,194.6 million in 2024 and $1,058.5 million in 2023.

Earnings are driven by the continuous introduction of next-generation technologies and computer assisted vacuum thrombectomy systems. However, when the company introduces a new product designed to replace an existing one, sales of the earlier generation naturally decline.

What protects it: the moat

Management claims that proprietary technologies, specialized physician relationships, and an efficient innovation process protect its market position.

Penumbra attributes its competitive standing to a corporate culture built on cooperation, a disciplined approach to product development, and deep connections with specialist physicians and healthcare providers. It also relies on regulatory clearances and approvals obtained for its thrombectomy, embolization, and access portfolios since 2007.

Because the filing provides these factors as assertions from management without independent verification of exclusionary power against dedicated rivals, investors must view these advantages as management's claims.

What growth costs

The company continually reinvests in research and development and clinical activities to support regulatory submissions and drive future product growth.

Research and development activities focus on creating new products and conducting clinical trials required for regulatory clearance. The company also invests heavily in commercial expansion to support its global sales footprint.

The filing does not disclose specific segregated budgets for ongoing maintenance capital expenditures versus growth-related outlays.

What could damage it

Uncertainty surrounding the pending acquisition by Boston Scientific could distract key personnel, alienate distribution partners, and permanently impair customer relationships.

If the proposed merger with Boston Scientific Corporation faces prolonged delays or fails to close, the disruption could cause key engineers, salespeople, and senior leaders to leave. At the same time, customers and vendors experiencing acquisition-related uncertainty may shift their business to competitors. Under certain termination circumstances defined in the merger agreement, the company could also be required to pay a substantial termination fee of $525.0 million, directly harming financial stability.

About Penumbra, Inc.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Other companies in Medical Devices